EOLS Stock Analysis: Evolus | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 528m USD | 12M Return: 33.3% | US30052C1071 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.36M
Qual. Beats: 0
Rev. Trend: 96.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 8.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Evolus, Inc. (EOLS) is a Newport Beach, California-based performance beauty company operating in the cash-pay aesthetic market across the United States, Canada, Europe, and Australia. The companys lead product is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation approved for the temporary improvement of moderate to severe glabellar lines (frown lines) in adults. Evolus also markets Evolysse, a line of injectable hyaluronic acid dermal fillers designed for areas such as the mid-face, nasolabial folds, lips, and eyes. Founded in 2012 and listed on Nasdaq since 2018, the company is classified within the Health Care sector and competes in the medical aesthetics space.
As a small-cap pharmaceuticals company, Evolus operates in the consumer-funded portion of medical aesthetics, where treatments are paid out-of-pocket rather than reimbursed by insurance. Its neurotoxin (Jeuveau) competes in the same category as established products like Botox, Dysport, and Xeomin, while its hyaluronic acid filler line (Evolysse) targets the broader dermal filler market alongside brands such as the Juvéderm and Restylane families.
- Jeuveau gains share against Botox in cash-pay aesthetics
- Evolysse injectable launch broadens product portfolio beyond neurotoxins
- International expansion into Europe and Australia drives revenue growth
| Net Income: -34.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA 12.95 > 1.0 |
| NWC/Revenue: 21.74% < 20% (prev 29.22%; Δ -7.48% < -1%) |
| CFO/TA -0.06 > 3% & CFO -15.4m > Net Income -34.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.9m) vs 12m ago 2.15% < -2% |
| Gross Margin: 66.25% > 18% (prev 66.63%; Δ -0.38% > 0.5%) |
| Asset Turnover: 132.7% > 50% (prev 121.5%; Δ 11.27% > 0%) |
| Interest Coverage Ratio: -1.43 > 6 (EBIT TTM -23.2m / Interest Expense TTM 16.2m) |
| A: 0.28 (Total Current Assets 167.5m - Total Current Liabilities 98.7m) / Total Assets 248.0m |
| B: -2.74 (Retained Earnings -679.8m / Total Assets 248.0m) |
| C: -0.10 (EBIT TTM -23.2m / Avg Total Assets 238.4m) |
| D: -0.11 (Book Value of Equity -30.9m / Total Liabilities 278.9m) |
| Altman-Z'' = -7.88 = D |
| DSRI: 1.15 (Receivables 62.4m/47.7m, Revenue 316.5m/277.9m) |
| GMI: 1.01 (GM 66.63% / 66.25%) |
| AQI: 0.88 (AQ_t 0.28 / AQ_t-1 0.32) |
| SGI: 1.14 (Revenue 316.5m / 277.9m) |
| TATA: -0.08 (NI -34.3m - CFO -15.4m) / TA 248.0m) |
| Beneish M = -2.88 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at USD 7.97 with a total of 398,309 shares traded. Over the past week, the price has changed by +1.40%, over one month by -11.20%, over three months by +11.47% and over the past year by +33.28%.
Current recommended Stop Loss: 7.20 (which is 9.7% or 2.1 ATR below the current price).
Evolus has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy EOLS.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15 | 88.2% |
P/E Forward = 16.7224
P/S = 1.6675
P/B = 53.7058
Revenue TTM = 316.5m USD
EBIT TTM = -23.2m USD
EBITDA TTM = -12.9m USD
Long Term Debt = 156.7m USD (from longTermDebt, last quarter)
Short Term Debt = 2.57m USD (from shortTermDebt, last quarter)
Debt = 172.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.06m
Net Debt = 127.7m USD (calculated: Debt 172.9m - CCE 45.2m)
Enterprise Value = 655.4m USD (527.7m + Debt 172.9m - CCE 45.2m)
Interest Coverage Ratio = -1.43 (Ebit TTM -23.2m / Interest Expense TTM 16.2m)
EV/FCF = -32.50x (Enterprise Value 655.4m / FCF TTM -20.2m)
FCF Yield = -3.08% (FCF TTM -20.2m / Enterprise Value 655.4m)
FCF Margin = -6.37% (FCF TTM -20.2m / Revenue TTM 316.5m)
Net Margin = -10.85% (Net Income TTM -34.3m / Revenue TTM 316.5m)
Gross Margin = 66.25% ((Revenue TTM 316.5m - Cost of Revenue TTM 106.8m) / Revenue TTM)
Gross Margin QoQ = 68.00% (prev 64.75%)
Tobins Q-Ratio = 2.64 (Enterprise Value 655.4m / Total Assets 248.0m)
Interest Expense / Debt = 9.38% (Interest Expense 16.2m / Debt 172.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -18.3m (EBIT -23.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.70 (Total Current Assets 167.5m / Total Current Liabilities 98.7m)
Debt / Equity = -5.59 (negative equity) (Debt 172.9m / totalStockholderEquity, last quarter -30.9m)
Debt / EBITDA = -9.86 (negative EBITDA) (Net Debt 127.7m / EBITDA -12.9m)
Debt / FCF = -6.33 (negative FCF - burning cash) (Net Debt 127.7m / FCF TTM -20.2m)
Total Stockholder Equity = -27.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.40% (Net Income -34.3m / Total Assets 248.0m)
RoE = 123.1% (negative equity) (Net Income TTM -34.3m / Total Stockholder Equity -27.9m)
RoCE = -18.00% (EBIT -23.2m / Capital Employed (Equity -27.9m + L.T.Debt 156.7m))
RoIC = -13.47% (negative operating profit) (NOPAT -18.3m / Invested Capital 136.0m)
WACC = 8.40% (E(527.7m)/V(700.6m) * Re(8.72%) + D(172.9m)/V(700.6m) * Rd(9.38%) * (1-Tc(0.21)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.58 | Cagr: 5.22%
[DCF] Fair Price = unknown (Cash Flow -20.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 96.84 | Revenue CAGR: 19.85% | SUE: 0.53 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.06 | Chg30d=+14.29% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.05 | Chg30d=-5.56% | Revisions=+62% | GrowthEPS=+89.2% | GrowthRev=+12.4%
EPS next Year (2027-12-31): EPS=0.29 | Chg30d=+13.37% | Revisions=+57% | GrowthEPS=+715.8% | GrowthRev=+17.4%
[Analyst] Revisions Ratio: +67% (up=11, down=1)